All In Biotech

Drug Trial Radar · NCT01555151

Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma

A Randomized, Double-blind, Double-dummy, 4-week Treatment, Parallel-group Study to Evaluate the Efficacy and Safety of Two Doses of Mometasone Furoate Delivered Via Concept1 or Twisthaler® in Adult and Adolescent Patients With Persistent Asthma

Last checked: Nov 19, 2026Latest source record: May 1, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 739 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

739

Actual

Start

Jul 2012

Primary completion

Jul 2013

Study completion Jul 2013

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 15, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy, safety and pharmacokinetics of Mometasone furoate delivered via Concept1 device or Twisthaler® device in adult and adolescent patients with persistent asthma.

Conditions

  • Asthma

Interventions

  • Mometasone furoateDrug

    Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device

  • Concept 1Device

    A single dose dry powder inhaler (SDDPI)

  • TwisthalerDevice

    A single dose dry powder inhaler (SDDPI)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Trough Forced Expiratory Volume in 1 Second (FEV1)Time frame: Day 29

Locations

165 sites in 17 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Kortrijk, Belgium, Belgium

  • Novartis Investigative Site

    Liège, Belgium, Belgium

  • Novartis Investigative Site

    Niagara Falls, Ontario, Canada

  • Novartis Investigative Site

    Windsor, Ontario, Canada

  • Novartis Investigative Site

    Mirabel, Quebec, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Québec, Quebec, Canada

  • Novartis Investigative Site

    Trois-Rivières, Quebec, Canada

  • Novartis Investigative Site

    Kohtla-Järve, Estonia, Estonia

  • Novartis Investigative Site

    Tallinn, Estonia, Estonia

  • Novartis Investigative Site

    Tartu, Estonia, Estonia

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Goch, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    Berlin, Germany, Germany

  • Novartis Investigative Site

    Berlin, Germany, Germany

  • Novartis Investigative Site

    Berlin, Germany, Germany

  • Novartis Investigative Site

    Berlin, Germany, Germany

  • Novartis Investigative Site

    Berlin, Germany, Germany

  • Novartis Investigative Site

    Berlin, Germany, Germany

  • Novartis Investigative Site

    Essen, Germany, Germany

  • Novartis Investigative Site

    Hamburg, Germany, Germany

  • Novartis Investigative Site

    Leipzig, Germany, Germany

  • Novartis Investigative Site

    Lübeck, Germany, Germany

  • Novartis Investigative Site

    Reinfeld, Germany, Germany

  • Novartis Investigative Site

    Schwerin, Germany, Germany

  • Novartis Investigative Site

    Baja, Hungary

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Gödöllő, Hungary

  • Novartis Investigative Site

    Győr, Hungary

  • Novartis Investigative Site

    Gyula, Hungary

  • Novartis Investigative Site

    Kistelek, Hungary

  • Novartis Investigative Site

    Makó, Hungary

  • Novartis Investigative Site

    Mohács, Hungary

  • Novartis Investigative Site

    Mosonmagyaróvár, Hungary

  • Novartis Investigative Site

    Nagykanizsa, Hungary

  • Novartis Investigative Site

    Szombathely, Hungary

Showing 40 of 165 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.